Bio-Techne (TECH)

• Market cap: $7.6B
• 1 day: -3.76%
• 5 days: -2.35%
• 1 month: -23.14%
• 3 months: -36.57%
• 6 months: -31.43%
• Year to date: -32.71%
• 1 year: -23.32%
• 5 years: 260.03%
• 10 years: 662.28%
• Sector: Healthcare
• Industry: Biotechnology

About: Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Employees: 3,100

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

921% more call options, than puts

Call options by funds: $12.9M | Put options by funds: $1.27M

40% more first-time investments, than exits

New positions opened: 70 | Existing positions closed: 50

12% more repeat investments, than reductions

Existing positions increased: 216 | Existing positions reduced: 193

2.32% more ownership

Funds ownership: 96.25% [Q3] → 98.57% (+2.32%) [Q4]

2% more funds holding

Funds holding: 553 [Q3] → 563 (+10) [Q4]

8% less capital invested

Capital invested by funds: $12.2B [Q3] → $11.3B (-$917M) [Q4]

40% less funds holding in top 10

Funds holding in top 10: 10 [Q3] → 6 (-4) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $68 41% upside
• Avg. target: $79 64% upside
• High target: $90 87% upside

6 analyst ratings

• positive: 3 50%
• neutral: 3 50%
• negative: 0 0%

Evercore ISI Group Daniel Markowitz 0% 1-year accuracy 0 / 2 met price target	56% upside $75	Outperform Initiated	18 Mar 2025
Citigroup Patrick Donnelly 26% 1-year accuracy 8 / 31 met price target	46% upside $70	Neutral Maintained	4 Mar 2025
Baird Catherine Schulte 0% 1-year accuracy 0 / 20 met price target	41% upside $68	Neutral Downgraded	19 Feb 2025
RBC Capital Conor McNamara 5% 1-year accuracy 2 / 37 met price target	66% upside $80	Sector Perform Maintained	6 Feb 2025
Scotiabank Sung Ji Nam 4% 1-year accuracy 1 / 24 met price target	87% upside $90	Sector Outperform Maintained	6 Feb 2025